Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.75 Billion KRW | -105.53% |
| 2022 | 140.22 Billion KRW | 8511.54% |
| 2021 | 1.62 Billion KRW | 645.4% |
| 2020 | -298.55 Million KRW | -231.66% |
| 2019 | 226.76 Million KRW | -89.96% |
| 2018 | 2.25 Billion KRW | -12.82% |
| 2017 | 2.59 Billion KRW | 5.54% |
| 2016 | 2.45 Billion KRW | -5.22% |
| 2015 | 2.58 Billion KRW | 6.54% |
| 2014 | 2.43 Billion KRW | 77.17% |
| 2013 | 1.37 Billion KRW | 3.93% |
| 2012 | 1.32 Billion KRW | -70.47% |
| 2011 | 4.47 Billion KRW | -0.39% |
| 2010 | 4.48 Billion KRW | -63.02% |
| 2009 | 12.13 Billion KRW | -33.45% |
| 2008 | 18.23 Billion KRW | -10.84% |
| 2007 | 20.45 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.29 Billion KRW | -304.24% |
| 2024 Q2 | -3 Billion KRW | 8.96% |
| 2023 FY | -7.75 Billion KRW | -105.53% |
| 2023 Q1 | -3.08 Billion KRW | -180.72% |
| 2023 Q4 | -816.22 Million KRW | 44.41% |
| 2023 Q3 | -1.46 Billion KRW | 43.86% |
| 2023 Q2 | -2.61 Billion KRW | 15.35% |
| 2022 Q1 | 1.28 Billion KRW | 1613.89% |
| 2022 Q3 | 4.32 Billion KRW | -96.69% |
| 2022 Q4 | 3.82 Billion KRW | -11.46% |
| 2022 Q2 | 130.78 Billion KRW | 10063.87% |
| 2022 FY | 140.22 Billion KRW | 8511.54% |
| 2021 Q4 | -84.99 Million KRW | 80.86% |
| 2021 FY | 1.62 Billion KRW | 645.4% |
| 2021 Q1 | -523.64 Million KRW | 52.75% |
| 2021 Q2 | -744.69 Million KRW | -42.21% |
| 2021 Q3 | -444.07 Million KRW | 40.37% |
| 2020 Q1 | 78.61 Million KRW | -46.17% |
| 2020 Q3 | -396.9 Million KRW | 23.87% |
| 2020 Q2 | -521.36 Million KRW | -763.16% |
| 2020 FY | -298.55 Million KRW | -231.66% |
| 2020 Q4 | -1.1 Billion KRW | -179.19% |
| 2019 Q3 | -576.32 Million KRW | -47.22% |
| 2019 FY | 226.76 Million KRW | -89.96% |
| 2019 Q1 | -435.36 Million KRW | -167.84% |
| 2019 Q4 | 146.05 Million KRW | 125.34% |
| 2019 Q2 | -391.48 Million KRW | 10.08% |
| 2018 Q2 | 198.69 Million KRW | -88.18% |
| 2018 Q1 | 1.68 Billion KRW | 430.25% |
| 2018 FY | 2.25 Billion KRW | -12.82% |
| 2018 Q3 | -263.27 Million KRW | -232.5% |
| 2018 Q4 | 641.72 Million KRW | 343.74% |
| 2017 Q1 | 1.73 Billion KRW | 249.89% |
| 2017 Q4 | 317.06 Million KRW | -46.1% |
| 2017 Q3 | 588.21 Million KRW | 1014.79% |
| 2017 Q2 | -64.3 Million KRW | -103.7% |
| 2017 FY | 2.59 Billion KRW | 5.54% |
| 2016 Q1 | 479.84 Million KRW | 245.15% |
| 2016 FY | 2.45 Billion KRW | -5.22% |
| 2016 Q4 | 496.14 Million KRW | -22.13% |
| 2016 Q3 | 637.17 Million KRW | -24.26% |
| 2016 Q2 | 841.27 Million KRW | 75.32% |
| 2015 FY | 2.58 Billion KRW | 6.54% |
| 2015 Q4 | -330.58 Million KRW | -183.44% |
| 2015 Q3 | 396.21 Million KRW | -71.5% |
| 2015 Q2 | 1.39 Billion KRW | 22.65% |
| 2015 Q1 | 1.13 Billion KRW | 78.88% |
| 2014 FY | 2.43 Billion KRW | 77.17% |
| 2014 Q1 | 1.11 Billion KRW | 351.1% |
| 2014 Q4 | 633.71 Million KRW | -14.71% |
| 2014 Q3 | 743 Million KRW | 1366.58% |
| 2014 Q2 | -58.66 Million KRW | -105.27% |
| 2013 Q3 | 198.68 Million KRW | -82.55% |
| 2013 Q4 | -443.09 Million KRW | -323.01% |
| 2013 FY | 1.37 Billion KRW | 3.93% |
| 2013 Q1 | 477.9 Million KRW | -82.54% |
| 2013 Q2 | 1.13 Billion KRW | 138.22% |
| 2012 Q4 | 2.73 Billion KRW | 233.47% |
| 2012 Q2 | -811.54 Million KRW | -156.15% |
| 2012 FY | 1.32 Billion KRW | -70.47% |
| 2012 Q3 | -2.05 Billion KRW | -152.66% |
| 2012 Q1 | 1.44 Billion KRW | 734.77% |
| 2011 Q4 | 173.15 Million KRW | -79.47% |
| 2011 Q1 | 1.73 Billion KRW | 1008.61% |
| 2011 Q2 | 1.71 Billion KRW | -1.05% |
| 2011 FY | 4.47 Billion KRW | -0.39% |
| 2011 Q3 | 843.52 Million KRW | -50.9% |
| 2010 FY | 4.48 Billion KRW | -63.02% |
| 2010 Q4 | -191.06 Million KRW | -116.24% |
| 2010 Q3 | 1.17 Billion KRW | 17.25% |
| 2010 Q2 | 1 Billion KRW | -59.87% |
| 2010 Q1 | 2.49 Billion KRW | -25.89% |
| 2009 Q2 | 1.68 Billion KRW | -60.56% |
| 2009 Q3 | 2.79 Billion KRW | 66.27% |
| 2009 Q1 | 4.26 Billion KRW | 27.07% |
| 2009 Q4 | 3.37 Billion KRW | 20.55% |
| 2009 FY | 12.13 Billion KRW | -33.45% |
| 2008 Q4 | 3.35 Billion KRW | -24.46% |
| 2008 Q3 | 4.44 Billion KRW | -9.22% |
| 2008 Q2 | 4.89 Billion KRW | -11.54% |
| 2008 Q1 | 5.53 Billion KRW | 17.19% |
| 2008 FY | 18.23 Billion KRW | -10.84% |
| 2007 FY | 20.45 Billion KRW | 0.0% |
| 2007 Q4 | 4.72 Billion KRW | 9.68% |
| 2007 Q3 | 4.3 Billion KRW | -28.47% |
| 2007 Q2 | 6.02 Billion KRW | 12.51% |
| 2007 Q1 | 5.35 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 2227.644% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 110.088% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 90.252% |
| HANDOK Inc. | 12.57 Billion KRW | 161.66% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -289.919% |
| Yuhan Corporation | 74.56 Billion KRW | 110.402% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 169.384% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 57.012% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 103.449% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 353.793% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 154.048% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 1400.472% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 904.766% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 128.693% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 2227.644% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 292.285% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 88.912% |
| JW Holdings Corporation | 143.66 Billion KRW | 105.399% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 85.48% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 103.145% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 107.733% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 83.634% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 211.97% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 219.858% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 188.83% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 2227.644% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 115.904% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 105.814% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 107.733% |
| Yuhan Corporation | 74.56 Billion KRW | 110.402% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 137.074% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 348.799% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 118.039% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 107.733% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 137.863% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 114.115% |
| CKD Bio Corp. | -20.15 Billion KRW | 61.513% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 124.063% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 130.654% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 123.846% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 83.634% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 123.399% |
| Boryung Corporation | 68.26 Billion KRW | 111.361% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 79.315% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 154.048% |
| JW Lifescience Corporation | 32.09 Billion KRW | 124.169% |